Minerva Neurosciences | NERV - Interest Expense On Debt


Minerva Neurosciences reported $2.31M in Interest Expense on Debt for its fiscal quarter ending in June of 2024.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Adma Biologics USD 1.63M 54K Dec/2025
ALKERMES USD 12.28M 7.63M Dec/2025
AstraZeneca USD 484M 181M Dec/2025
BioCryst Pharmaceuticals USD 14.14M 5.53M Dec/2025
Bristol-Myers Squibb USD 411M 21M Mar/2026
Cipla INR 140.3M 8.5M Dec/2025
Compugen USD 954K 116K Sep/2025
CSL USD 215M 111M Dec/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Esperion Therapeutics USD 22.64M 585K Dec/2025
GlaxoSmithKline GBP 167M 21M Mar/2026
Grifols EUR 156.07M 31.46M Sep/2025
Halozyme Therapeutics USD 4.91M 615K Dec/2025
Ionis Pharmaceuticals USD 17M 1000K Mar/2026
J&J USD 43M 25M Mar/2026
Merck USD 479M 67M Mar/2026
Minerva Neurosciences USD 2.31M 60K Jun/2024
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Novartis USD 343M 39M Mar/2026
Novavax USD 5.82M 342K Dec/2025
Pfizer USD 711M 59M Dec/2025
Roche Holding CHF 304M 7.5M Jun/2025
Sanofi EUR 178M 203M Mar/2026
Takeda JPY 123.63B 40.49B Dec/2025
Vanda Pharmaceuticals 601.14M 23.61M Sep/2025